𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dose of contrast material in the MR imaging evaluation of central nervous system tumors

✍ Scribed by William T. C. Yuh; John I. Halloran; Nina A. Mayr; David J. Fisher; Hoang D. Nguyen; Teresa M. Simonson


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
890 KB
Volume
4
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis


THERE HAS BEEN controversy regarding the appropriate use of magnetic resonance (MR) contrast agents in the evaluation of central nervous system (CNS) tumors. When MR imaging was first available in clinical practice in the early 1980s. contrast agents were thought to be unnecessary because of the excellent tissue contrast provided by nonenhanced MR images.

After the introduction of the first MR contrast agent, gadopentetate dimeglumine (Magnevist; Berlex Laboratories, Wayne, N J ) (standard dose, 0.1 mmoV kg), contrast material-enhanced MR imaging provided improved lesion detection, delineation, and specificity. Recently, several investigators have suggested that examinations with doses of contrast material greater than the standard dose further improve detection of small or early metastases and improve delineation of gliomas ( 1 4 ) . Higher doses are often avoided because of concern over increased examination cost, potential side effects, and loss of potency of the contrast material due to the T2 shortening effect. In fact, doses less than the standard dose have been used in the evaluation of brain tumors. Some believe that, in addition to saving money, lower doses are just as effective in the detection of CNS lesions.

No single dose of MR contrast agent is optimal or adequate for the evaluation of all types of brain tumors. An understanding of a l l the factors influencing lesion conspicuity is of paramount importance in deciding on the optimal dose of contrast material for a specific MR imaging examination. The major factors influencing lesion detection include lesion contrast, size, location, and type. This review addresses the theories behind the importance of lesion contrast-specif-Index terms: Brain neoplasms. dlagnosls. 10.12143 -Brain neoplasms. MR. 10.12143 * Contrast enhancement * Nervous system. MR. 10.12143 -Nervous system. neoplasms. 10.12143 JMRl 1994. 4:243-249 Abbrevhtions: lntenslty ratlo. MTC = magnetlzatlon transfer contrast. CNS = central nervous system. L/B = lesion-to-background signal I From the Department of Radiology. Unlverslty of Iowa College of Mediclne, 200 Hawklns Dr. Iowa Clty. IA 52242.


📜 SIMILAR VOLUMES


MR imaging of the central nervous system
✍ Peter A. Rinck; Rasmus Svihus; Patricia de Francisco 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 755 KB

## Abstract A group of 70 professional divers and 47 healthy control subjects who had never dived were examined with magnetic resonance (MR) imaging to determine the prevalence of focal white matter changes in the brain. Spots of high signal intensity in white matter on proton density‐and/or T2‐wei

Comparison of the safety of the standard
✍ Marit G. Svaland; Bjørg Lundby; Doris T. Kristoffersen 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 514 KB

## Abstract This study compared the safety and tolerability of gadodiamide injection at the standard dose (0.1 mmol/kg) and at a higher dose (0.3 mmol/kg) in 289 patients participating in a parallel group multiple independent trial program. All patients had a known or suspected central nervous syst

Pitfalls of contrast-enhanced imaging in
✍ Michael Brant-Zawadzki 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB

## Abstract This brief review covers the evolving clinical role of paramagnetic contrast agents in magnetic resonance imaging of the central nervous system, with particular emphasis on potential pitfalls. The safety and efficacy of Gd‐DTPA is now well‐established. Approximately 35–40% of all scans

Magnetic resonance imaging in the evalua
✍ Roger J. Packer; Robert A. Zimmerman; Larissa T. Bilaniuk 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Neurologic and neuropsychologic treatment related sequelae are increasingly encountered in children with cancer, but conventional means of neurologic investigation are insensitive to the presence and extent of damage. Magnetic resonance imaging (MRI) has shown brain damage not demonstrable by other

Magnetic resonance imaging–guided adopti
✍ Raghvendra S. Sengar; Laima Spokauskiene; Daniel P. Steed; Patricia Griffin; Nor 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

## Abstract Dendritic cells (DCs) are the most effective antigen‐presenting cells (APCs) and are used in a variety of immunotherapeutic approaches. Adoptive cellular immunotherapy (ACI) of cancer using DCs has attracted much interest due to their capacity to promote immunity in prophylactic and the